What Happened

Science Corporation, founded by former Neuralink president Max Hodak, has placed its PRIMA retinal implant in the eye of the first patient diagnosed with Stargardt disease. The implant is a 2 mm × 2 mm chip that sits at the back of the eye, acting as an artificial photoreceptor. The patient, who received the device in May, has already shown early signs of visual improvement: during the first rehabilitation session he saw a single letter, and in the second session he was able to read a word.

The development was announced by Hodak during his TechCrunch Disrupt presentation. He framed the achievement as part of a larger vision in which retinal prostheses, cochlear implants and motor prostheses are all considered types of brain‑computer interfaces (BCIs). While PRIMA is already commercially available in Europe for patients who have lost vision to geographic atrophy (a form of age‑related macular degeneration), the Stargardt case demonstrates that the same platform can be adapted to a different, currently incurable disease.

The Key Details

  • Device: PRIMA, a 2 mm × 2 mm retinal implant placed where photoreceptors have degenerated. It works with camera‑equipped glasses that stream visual data to the chip, providing high‑contrast black‑and‑white vision with a narrow field of view (described as “looking through a straw”).
  • Patient: First human with Stargardt disease, treated at Sydney Eye Hospital in Australia during May 2026.
  • Disease: Stargardt disease affects the outer retina, causing gradual death of light‑sensing cells while sparing the inner retina. About 150,000 people worldwide have lost vision due to the condition.
  • Early Results: The patient saw a letter in the first rehab session and read a word in the second.
  • Future Roadmap: Hodak said a next‑generation device is slated for human trials within a year, with the goal of approaching native visual acuity within five years.
  • BCI Strategy: Science Corporation’s BCI sensor will sit on top of the brain (inside the skull) rather than being inserted into brain tissue, differentiating it from Neuralink’s approach. The company plans to target neurodegenerative diseases and stroke as early clinical indications, with a long‑term mission to understand how the brain creates the mind and to build engineered brains.
  • Commercial Context: PRIMA is already available in Europe for geographic atrophy patients, providing a revenue stream that funds the broader BCI research program.

Why It Matters

The implantation represents a tangible step forward for a class of devices that blur the line between medical prosthetics and brain‑computer interfaces. By demonstrating that a retinal implant can restore functional vision in a new disease model, Science Corporation validates its claim that retinal prostheses are a viable branch of BCI technology. This could accelerate regulatory acceptance and investment for similar neuro‑prosthetic approaches. Additionally, the early functional results—reading a word after just two rehab sessions—show that the technology can deliver meaningful visual information quickly, which may influence patient expectations and clinical trial designs for other vision‑restoring devices.

What It Means for Readers

  • For patients with inherited retinal diseases: The PRIMA implant offers a potential pathway to regain some central vision, though the current field of view is limited and the vision is black‑and‑white. Future generations aim to broaden the view and improve color perception.
  • For smartphone and wearable users: The camera‑glass system that feeds visual data to the implant could inspire new assistive technologies that integrate with smart devices, though the current hardware is specialized and not consumer‑ready.
  • For investors and tech enthusiasts: The project illustrates a “medical‑first” strategy for BCI development, where revenue from vision restoration funds more ambitious brain‑interface work. This model could be replicated in other neuro‑technology startups.
  • For clinicians: The Sydney Eye Hospital trial provides a real‑world benchmark for rehabilitation protocols and outcome measures for retinal prostheses, which could inform treatment plans for other prosthetic vision devices.
  • For developers of AI‑driven visual processing: The system’s reliance on real‑time camera input and conversion to electrical signals highlights the intersection of hardware, AI, and neuroscience, suggesting opportunities for smarter image‑to‑signal algorithms.

What Happens Next

Science Corporation has announced a next‑generation implant slated for human trials within the next year, with the goal of expanding the visual field and moving closer to native acuity within five years. The company also plans to pursue an unannounced first clinical indication for a neurodegenerative disease and is exploring stroke rehabilitation applications. Continued progress will depend on regulatory approvals, manufacturing scalability, and further clinical data demonstrating functional benefits.

VANTIX Takeaway

The PRIMA implant’s success in a Stargardt patient shows that retinal prostheses can move beyond experimental stages and deliver usable vision, validating the broader BCI vision that retinal, cochlear and motor devices are all part of a unified neuro‑technology ecosystem. For readers, the key takeaway is that a technology originally designed for one vision‑loss condition is already being applied to another, suggesting a faster, more flexible pathway for future neuro‑prosthetic innovations.

--- Tags: Science Corporation, Max Hodak, PRIMA, Stargardt disease, retinal prosthesis, brain‑computer interface, Sydney Eye Hospital, BCI, vision restoration, neuro‑technology